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esponsibility of Xi’Abstract This study was designed to examine the interaction of sulfamethoxazole (SMZ) with
human serum albumin(HSA). Spectroscopic analysis of the emission quenching at different
temperatures revealed that the quenching mechanism of human serum albumin by SMZ was static
mechanism. The binding constant values for the SMZ–HSA system were obtained to be 22,500 L/mol
at 288 K, 15,600 L/mol at 298 K, and 8500 L/mol at 308 K. The distance r between donor and
acceptor was evaluated according to the theory of Föster energy transfer. The results of spectroscopic
analysis and molecular modeling techniques showed that the conformation of human serum albumin
had been changed in the presence of SMZ. The thermodynamic parameters, namely enthalpy change
(ΔH0) 36.0 kJ/mol, entropy change (ΔS0) 41.3 J/mol K and free energy change (ΔG0) 23.7 kJ/
mol, were calculated by using van’t Hoff equation. The effect of common ions on the binding of SMZ
to HSA was tested.
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Human serum albumin (HSA), the most abundant human plasma
protein, contains a single polypeptide chain of 585 amino acids. It is
largely helical and is composed of three structurally homologous
domains (I, II and III) [1]. Each domain contains 10 helices; helices
1–6 form the respective sub-domains A and helices 7–10 compriser B.V. All rights reserved. This is an open access article under the CC BY-
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within two hydrophobic pockets in sub-domains IIA and IIIA,
namely sites I and II. Seven binding sites are localized for fatty acids
in sub-domains IB, IIIA, IIIB and on the sub-domain interfaces [2].
HSA has a high afﬁnity metal binding site at the N-terminus [3]. The
multiple binding sites underlie the exceptional ability of HSA to
interact with many organic and inorganic molecules and make this
protein an important regulator of intercellular ﬂuxes, as well as the
pharmacokinetic behavior of many drugs [1,2]. Plasma protein
binding of drugs assumes great importance since it inﬂuences their
pharmacokinetic and pharmacodynamic properties, and may also
cause interference with the binding of other endogenous and/or
exogenous ligands as a result of overlap of binding sites and/or
conformational changes. Therefore, detailed investigation of drug–
protein interaction assumes signiﬁcance for thorough understanding
of the pharmacokinetic behavior of a drug and for the design of
analogs with effective pharmacological properties. Hence, it becomes
an important research ﬁeld in chemistry, life sciences and clinical
medicine.
Recently, many optical techniques have been carried out to
investigate the interaction of proteins and drugs, because these
methods are sensitive and relatively easy to use [4,5]. Among these,
ﬂuorescence quenching is a useful method to study the reactivity of
chemical and biological systems since it allows non-instrusive
measurements of substances in low concentration under physiological
conditions [6–11]. It can reveal accessibility of quenchers to serum
albumins ﬂuorophores, which helps to understand serum albumin’s
binding mechanisms to compounds and provides clues to the nature
of the binding phenomenon. Fourier transform infrared (FT-IR), a
powerful technique for the study of hydrogen bonding, has recently
become very popular for structural characterization of proteins. The
most important advantage of FT-IR spectroscopy for biological
studies is that spectra of almost any biological system can be
obtained in a wide variety of environments.
Sulfamethoxazole (SMZ) [N-(5-methyl-3-iso-xazolyl) sulfanila-
mide] (Fig. 1) is a well known antibacterial drug. It is mainly used in
treating urinary tract and lower respiratory tract infections and gets
readily absorbed in the body [12]. The present study showed that
there was a major change in the ﬂuorescence and in structural
properties of HSA upon binding to SMZ, which has been utilized for
the characterization of different interaction parameters. In view of its
biological importance, we found it worthwhile to study the binding
of SMZ to HSA using various techniques viz., ﬂuorescence, FT-IR,
UV–vis and cyclic voltammetry, as it is not reported so far.2. Experimental
2.1. Equipments and spectral measurements
Fluorescence measurements were performed on a spectroﬂuori-
meter Model F-2000 (Hitachi, Tokyo, Japan) equipped with a
150 W Xenon lamp and a slit width of 5 nm. The infrared spectraFig. 1 Structure of sulfamethoxazole.were acquired on a Thermo Nicolet- 5700 FT-IR spectrometer
(Waltham, MA, USA) equipped with a germanium attenuated total
reﬂection (ATR) accessory, a DTGS KBr detector and a KBr beam
splitter. All spectra were recorded via the ATR method with a
resolution of 4 cm1 and 60 scans. The absorption spectra were
recorded on a double beam UV–vis spectrophotometer (Varian
CARY 50-BIO, Mulgrave Victoria, Australia) equipped with a
150 W Xenon lamp and a slit width of 5 nm.
2.2. Reagents and chemicals
Essentially fatty acid free HSA was obtained from Sigma
Chemical Company (St. Louis, USA). SMZ was obtained from
Sigma Chemical Company (St. Louis, USA). The solutions of
SMZ and HSA were prepared in 0.1 M phosphate buffer of pH 7.4
containing 0.15 M NaCl. HSA solution was prepared based on its
molecular weight of 66,500. The protein concentration was
determined spectrophotometrically using the extention coefﬁcient
of 36,500 L/mol cm [13]. Salts of different metals, phosphate,
acetate and urea were purchased from Merck (New Delhi, India).
Site probes viz., warfarin, ibuprofen and digitoxin purchased from
Sigma Chemical Company (St. Louis, USA) were initially
dissolved in minimum amount of methanol and then diluted with
distilled water. All other materials were of analytical reagent grade
and double distilled water was used throughout.
2.3. Methods
2.3.1. SMZ–HSA interactions by ﬂuorescence measurements
Appropriate volumes of the HSA solution (40 mL from 250 mM
stock) and SMZ solution (40 mL from 250 mM stock) were
transferred into a 5 mL conical ﬂask. The mixtures were diluted
with phosphate buffer solution (pH 7.4) to make the total volume
(2 mL) and then were shaken. Fluorescence measurements were
carried out by keeping the concentration of HSA ﬁxed at 5 mM and
that of SMZ varied from 5 to 60 mM. Fluorescence spectra were
recorded at 288, 298 and 308 K in the range of 300–500 nm upon
excitation at 280 nm in each case.
2.3.2. FT-IR measurements
The FT-IR spectra of HSA (5 mM) in the presence and absence of
SMZ were recorded in the range of 1300–1800 cm1. The molar
ratio of HSA to drug was maintained at 1:4. The corresponding
absorbance contributions of buffer and free SMZ solutions were
recorded and digitally subtracted with the same instrumental
parameters.
2.3.3. Energy transfer between protein and SMZ
The absorption spectrum of SMZ (5 mM) was recorded in the
range of 300–500 nm. The emission spectrum of HSA (5 mM) was
also recorded in the range of 300–500 nm. Then, the efﬁciency of
transfer can be used to evaluate the distance between the ligand
and the tryptophan residues in the protein.
2.3.4. Displacement experiments
The displacement experiments were performed using the site
probes (warfarin, ibuprofen and digitoxin) keeping the concentra-
tion of HSA and probe constant (each of 5 mM). SMZ was then
gradually added to the HSA-site probe mixtures. The ﬂuorescence
quenching titration was used as before to determine the binding
Fig. 2 Fluorescence spectra of HSA in the presence of SMZ. HSA
concentration was 5 mM (a), SMZ concentration was at 5 mM(b),
10 mM (c), 15 mM (d), 20 mM (e), 25 mM (f), 30 mM (g), 35 mM (h),
40 mM (i), 45 mM (j), 50 mM (k), 55 mM (l) and 60 mM (m).
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probes, warfarin, ibuprofen and digitoxin for sites I, II and III [14].
2.3.5. Absorption measurements
The absorption spectra of HSA in the presence and absence of
SMZ were noted in the range of 200–320 nm. HSA concentration
was ﬁxed at 5 mM while that of SMZ varied from 5 to 25 mM.
2.3.6. Voltametric interaction of SMZ with HSA
The concentration of SMZ was kept at 1 104 M and the HSA
solution was added at different concentrations in the range of
(1.25–12.5) 106 M. A given SMZ–HSA system was stirred for
10 s and then the cyclic voltammetry experiment was performed at
7.4 pH (scan rate¼0.1 V/s).
2.3.7. Preparation of different conformers of HSA
HSA exists in different conformational states as N, F and I forms
[15]. The N, F and I conformations were prepared by mixing
40 μL of HSA monomer stock solution (250 μM) with 1960 μL of
pH 7 (60 mM phosphate), pH 3.5 (10 mM acetate) buffers, and
10 M urea was used as per the required concentration. The
existence of different isomers in the experimental preparations
was conﬁrmed with various ﬂuorescence properties of different
forms. Different isomers in the experimental preparations were
conﬁrmed with various spectroscopic properties of different forms
viz., max of N form¼344 (ext. 295 nm), 339.3 (ext. 280 nm), max
of F form¼344 (ext. 295 nm), 334.6 (ext. 280 nm), max of I
form¼344 (ext. 295 nm), 341 (ext. 280 nm) and ﬂuorescence
intensities of N, F and I forms were 101, 115 and 71, respectively.
2.3.8. Effects of common ions
The effect of common ions viz. Mg2þ, Ni2þ, Co2þ, V5þ, NO3
 ,
SO4
2 and CH3COO
 on the binding constant of SMZ–HSA
system was investigated at 298 K by recording the ﬂuorescence
intensity in the range of 300–500 nm upon excitation at 280 nm.
The concentration of both HSA and common ion was ﬁxed at
5 mM. The solutions of anions were prepared from sodium salts
while chlorides of cations were used for preparing the solutions of
cations except for V5þ solution where ammonium metavanadate
was used. Under the experimental conditions, no cation gave
precipitate in phosphate buffer.3. Results and discussion
3.1. Analysis of ﬂuorescence quenching of HSA by SMZ
Fluorescence quenching is the decrease of the quantum yield of
ﬂuorescence from a ﬂuorophore induced by a variety of molecular
interactions with a quencher molecule. Generally, the ﬂuorescence
of HSA comes from tryptophan, tyrosine and phenylalanine
residues. The change of intrinsic ﬂuorescence intensity of HSA
was due to tryptophan residue when small molecules bound to
HSA. This viewpoint was well supported by the experimental
observations of Sulkowska [16]. The ﬂuorescence intensity of
HSA gradually decreased with increasing the concentration of
SMZ (Fig. 2), indicating that there was an interaction between
SMZ and HSA. It was clear that HSA had a strong ﬂuorescence
emission band at 333 nm by ﬁxing the excitation wavelength at
280 nm, while the drug SMZ had no intrinsic ﬂuorescence (Fig. 2).
A red shift in maximum emission wavelength of HSA (from 333to 339 nm) was observed upon the addition of SMZ probably due
to the loss of the compact structure of hydrophobic sub-domain
where tryptophan was placed (inset Fig. 2) [11]. Also SMZ–HSA
complex could quench the ﬂuorescence of HSA and change the
microenvironment of tryptophan residue. Hence, it was proposed
that the binding took place near Trp-214 and led to a conforma-
tional change with a local perturbation of the IIA binding site in
HSA. Under the experimental conditions, SMZ did not show any
ﬂuorescence intensity. SMZ caused a concentration-dependent
quenching of the intrinsic ﬂuorescence of HSA.
3.2. Binding parameters and mechanism
Quenching can be induced by dynamic and static processes.
Dynamic and static quenching can be distinguished based on their
differences in temperature dependence. Higher temperature results
in faster diffusion and larger amounts of collisional quenching. It
will typically lead to the dissociation of weakly bound complexes
and smaller amounts of static quenching. Therefore, the quenching
constant increases for dynamic quenching while it decreases for
static quenching with an increase in temperature. The possible
quenching mechanism can be deduced from the Stern–Volmer
plot. The Stern–Volmer plot for a representative drug–HSA system
is shown in Fig. 3. The Stern–Volmer plots were observed to be
linear for SMZ–HSA with the slopes decreasing with an increase
in temperatures. The values of KSV at different temperatures were
evaluated as 1.440 104, 0.910 104 and 0.580 104 L/mol,
respectively. The values of KSV at different temperatures indicated
the presence of static quenching mechanism in the interaction
between SMZ and HSA. In order to invoke this possibility, the
mechanism was assumed to involve dynamic quenching. The
equation for dynamic quenching is presented by Eq. (1) [17]
F0=F ¼ 1þ KSV½Q ¼ 1þ Kqτo½Q ð1Þ
where F and F0 are the ﬂuorescence intensities of HSA with
and without quencher, respectively. Kq, KSV, τo and [Q] are the
quenching rate constant, the dynamic quenching constant,
the average lifetime of the biomolecule without quencher and
the concentration of quencher, respectively.
Kq ¼KSV=Γo ð2Þ
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without quencher is 108 s [18], the quenching constant (Kq,
L/mol s) can be obtained by the slope using above equation,
0.91 1012 L/mol s (r¼0.983) for HSA at 298 K. The values of
Kq are given in Table 1. The maximum scatter collision quenching
constant, Kq of various quenchers with the biopolymer [19], is
reported to be 2 1010 L/mol s. The order of magnitude of Kq was
calculated to be 1012 for SMZ–HSA system in the present study.
So, the rate constant of the protein quenching procedure initiated
by SMZ is greater than the value of Kq for the scatter mechanism.
This implied that the quenching was not initiated by dynamic
collision but originated from the formation of a complex.3.3. Changes of the protein’s secondary structure induced by
drug binding
UV absorption spectrum is an important method and application to
explore the structural change and to know the complex formation
[20]. In order to obtain more information on SMZ–HSA interac-
tions, UV absorption spectra of drug, HSA and drug–HSA systems
were recorded. It was observed from Fig. 4 that the absorption of
HSA increased regularly upon the successive addition of SMZ.
The chromophore of SMZ–HSA gives very speciﬁc pattern of the
UV–vis spectrum with slightly duel absorbance spectra at a higher
concentration of SMZ in the system and the SMZ–HSA spectrum
shifts towards shorter wave length. The evidence clearly indicated
the interaction between SMZ and HSA. This was noticed due to
formation of a complex between the drug and HSA [20]. This also
indicated that the peptide strands of protein molecules extended
further more upon the addition of SMZ to HAS [20,21]. So, the
binding of SMZ to protein molecule might lead to change in
conformation of the protein [22].Fig. 3 The Stern–Volmer curves for the binding of SMZ to HSA at
288 K (a), 298 K (b), 308 K (c). λex¼280 nm, λem¼344 nm and
CHSA¼5 mM.
Table 1 Thermodynamic parameters of SMZ–HSA system.
Temp. (K) Binding constant (K)
( 104 L/mol)
Kq
( 1012 L/mol s)
Number of b
288 2.25070.001 1.44070.006 1.04
298 1.56070.003 0.91070.005 1.04
308 0.85070.002 0.58070.008 1.02Additional evidence regarding SMZ–HSA interactions was
obtained from FT-IR spectroscopic results. Infrared spectra of a
protein exhibit a number of amide bands due to the different
vibrations of the peptide moiety. Of all the amide modes of the
peptide group, amide I band is more sensitive to the changes in
protein secondary structure than amide II. Hence, the amide I band
is more useful for studies of secondary structure [23–27]. The
amides I and II peaks occur in the region of 1700–1600 cm1 and
1600–1500 cm1, respectively. Supplementary Fig. S1(a) and (b)
shows the FT-IR spectra of the SMZ free and SMZ bound form of
HSA with its difference absorption spectrum. Supplementary Fig.
S1(a), the FT-IR spectra of free HSA (subtracting the absorption of
the buffer solution from the spectrum of the protein solution) and
Supplementary Fig. S1(b), the FT-IR difference spectra of HSA
(subtracting the absorption of the SMZ–HSA free form that of
SMZ–HSA bound form) in phosphate buffer, CHSA¼5.0 and
CSMZ¼20 mM. The peak positions of amides I and II were found
to be shifted upon the addition of SMZ to HSA. The amide I band
was shifted from 1660 to 1654 cm1 for SMZ while the amide II
peak was shifted from 1545 to 1549 cm1 for SMZ. These results
indicated that both the SMZ interacted with the CO and CN groups
in the protein polypeptides. The SMZ–protein complexes caused
the rearrangement of the polypeptide carbonyl hydrogen-bonding
network and ﬁnally the reduction of the protein helical structure.
Supplementary Fig. S1 and Fig. 5 show a quantitative analysis of
the protein secondary structure of HSA before and after the
interaction with SMZ in phosphate buffer. According to the FT-
IR spectra of amide I and the curve-ﬁtted results (Fig. 5), theinding sites (n) ΔH0 (kJ/mol) ΔS0 (J/mol K) ΔG0(kJ/mol)
36.073.0 41.375.0 23.773.0
Fig. 4 Absorbance spectra of HSA, SMZ and HSA–SMZ system.
HSA concentration was at 5 mM(a). SMZ concentration for SMZ–
HSA system was at 5 (b), 10 (c), 15 (d), 20 (e), 25 (f), 30 (g), 35 (h)
and 40 mM (i). A concentration of 5 mM SMZ (x) was used for
SMZ only.
Fig. 5 Curve-ﬁtted amide I (1700–1600 cm1) regions of free HSA
(A) and SMZ–HSA (B) in buffer solution with CSMZ/CHSA¼1/1.
Fig. 6 The plot of log(F0F)/F vs. log[Q] for quenching of SMZ to
HSA at 288 K (a), 298 K (b) and 308 K(c) (λex¼280 nm, λem¼344
nm, CSMZ¼5–60 mM, CHSA¼5 mM).
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presence of SMZ were estimated. The data obtained from Fig. 5
suggested that upon SMZ–HSA complexes, the α-helix structures
were increased from 49.4% to 60.4%, β-sheet decreased slightly
from 36.5% to 31.5%, and β-turn structures decreased from 14.1%
to 8.1%. HSA and BSA are homolog proteins showing 78.1% of
sequence identity. BSA contains two tryptophan residues (Trp-212
and Trp-134), while HSA has one tryptophan (Trp-214). The BSA
three-dimensional structures are very similar to HSA. Based on our
spectroscopic data, SMZ binding to BSA and HSA occurs via
hydrophobic interactions. However, stronger SMZ–protein inter-
action was observed for HSA–SMZ with a binding constant (K) of
(1.56070.003) 104 L/mol at 298 K. The binding mode of SMZ–
HSA was increased the percentage of protein α-helix from 49.4%
(free HSA) to 60.4% in SMZ–HSA adduct. The increase in α-helix
and decrease in β-sheet structure are evidence for some degree of
stabilization of protein structure at a high SMZ concentration.
3.4. Apparent binding constant and binding sites
When small molecules bind independently to a set of equivalent
sites on a macromolecule, the equilibrium between free and bound
molecules could be represented by the equation [20] as
log F0FÞ=F ¼ log K þ n log Q½
 ð3Þwhere K and n are the binding constant and number of binding
sites, respectively. The values of K and n for SMZ–HSA system
were calculated from the intercept and slope of the plot of log
(F0F)/F versus log[Q] and the same plot for a representative
system, SMZ–HSA, is given in Fig. 6. The value of K is
signiﬁcant to understand the distribution of the drug in plasma
since the weak binding can lead to a short lifetime or poor
distribution, while strong binding can decrease the concentrations
of free drug in plasma. The values of K and n are summarized in
Table 1. It was noticed that the binding constant values decreased
with an increase in temperature due to reduction of the stability of
SMZ–HSA complexes. The values of n for SMZ–HSA were
noticed to be almost unity, indicating that there was one
independent class of binding sites on HSA for SMZ. Hence,
SMZ is most likely to be bound to the hydrophobic pocket located
in sub-domain IIA. That is to say, Trp-214 is near or within the
binding site [28].
Sudlow et al. [14] suggested two main distinct binding sites
(sites I and II) in HSA. Sites I and II of HSA show afﬁnity to
warfarin and ibuprofen, respectively. It is reported that digitoxin
binding is independent of sites I and II and digitoxin binds to site
III [29,30]. In order to establish the binding site in HSA for SMZ,
displacement experiments were performed using site probes,
warfarin, ibuprofen and digitoxin. For this, emission spectra of
ternary mixtures of SMZ, HSA and site probe were recorded. The
binding constant values of SMZ–HSA after the addition of the
site probes were evaluated to be (0.68070.001) 104 L/mol,
(1.54070.005) 104 L/mol and (1.55070.003) 104 L/mol
respectively. The values of binding constant indicated that SMZ
was not displaced by ibuprofen or by digitoxin. However,
warfarin showed a signiﬁcant displacement of SMZ, suggesting
that SMZ binding site on HSA is site I. Hence, site I located in
subdomain IIA near Trp-214 is the main binding site for SMZ
in HSA.3.5. Thermodynamic parameters
The thermodynamic parameters, enthalpy change (ΔH0) and
entropy change (ΔS0), of SMZ–HSA interaction are important
Fig. 7 The overlap of the ﬂuorescence spectrum of BSA and the
absorbance spectrum of SMZ (λex¼280 nm, λem¼344 nm, CHSA/
CSMZ¼1:1). The absorption spectrum of SMZ (5 mM) (a) and the
ﬂuorescence spectrum of HSA (5 mM) (b).
P.N. Naik et al.148for conﬁrming binding mode. For this purpose, the temperature
dependence of binding constant was studied. Binding studies were
carried out at 288, 298 and 308 K at which HSA did not undergo
any structural degradation. The molecular forces contributing to
protein interactions with small molecular substrates may include
van der Waals interactions, hydrogen bonds, electrostatic and
hydrophobic interactions and so on [20]. The thermodynamic
parameters were evaluated using the following equations:
log K ¼ ΔH
0
2:303RT
þ ΔS
0
2:303R
ð4Þ
ΔG0 ¼ΔH0TΔS0 ð5Þ
The plot of log K versus 1/T enabled the determination of the
values of ΔH0 and ΔS0 (Supplementary Fig. S2). Ross et al. [31]
have characterized the sign and magnitude of the thermodynamic
parameters associated with various individual kinds of interactions.
For typical hydrophobic interactions, both ΔH0 and ΔS0 are
positive, while these are negative for van der Waals forces and
hydrogen-bond formation in low dielectric media [31,32]. More-
over, the speciﬁc electrostatic interaction between ionic species in
an aqueous solution is characterized by positive ΔS0 value and
negative ΔH0 value (small). From Table 1, it can be seen that
both ΔH0 and ΔG0 have negative values, 36.0 kJ/mol and
23.7 kJ/mol, respectively. Negative values for ΔG0 and ΔH0
indicate that both binding processes occurred spontaneously and
the formation of both SMZ–HSA complexes was exothermic.
The negative values of ΔH0 (36.0 kJ/mol) and ΔS0
(41.3 J/mol K) for SMZ–HSA reveal that intermolecular forces
such as hydrophobic interaction, hydrogen bonds, and van der
Waals interaction are present in the system. In addition, the major
contribution to ΔG0 arising from the ΔH0 term rather than from
ΔS0 implies that the binding processes are enthalpy driven.
Accordingly, it was not possible to account for the thermodynamic
parameters of HSA–SMZ compound on the basis of a single
interaction molecular force model. It was more likely that
hydrophobic and hydrogen bond interactions were involved in
the binding process [32]. But SMZ might be considered to be
largely unionized under the experimental conditions, as can be
expected from its structure. Hence, electrostatic interaction can
be precluded from the binding process. Therefore, both hydrogen
bonds and hydrophobic interactions are assumed to play a major
role in the binding of SMZ to HSA.3.6. Energy transfer from HSA to SMZ
Fluorescence resonance energy transfer (FRET) is a distance-
dependent interaction between the different electronic excited
states of molecules in which excitation energy is transferred from
one molecule (donor) to another molecule (acceptor) without
emission of a photon from the former molecular system. The
efﬁciency of FRET depends mainly on the following factors: (i)
the extent of overlap between the donor emission and the acceptor
absorption, (ii) the orientation of the transition dipole of donor and
acceptor and (iii) the distance between the donor and acceptor. The
energy transfer effect is related not only to the distance between
the acceptor and the donor, but also on the critical energy transfer
distance R0. The spectral overlap between the ﬂuorescence
emission spectrum of free HSA and absorption spectrum of a
drug, SMZ, is shown in Fig. 7. The efﬁciency of energy transfer,
E, was determined according to Förster’s energy transfer theory[33]. The value of E was calculated using the equation
E¼ 1 F
F0
¼ R
6
0
R60 þ r6
ð6Þ
where F and F0 are the ﬂuorescence intensities of HSA in the
presence and absence of SMZ, r is the distance between the
acceptor and the donor, and R0 is the critical distance when the
transfer efﬁciency is 50%. The value of R0 was evaluated using the
equation
R60 ¼ 8:8 1025k2N4ΦJ ð7Þ
where k2 is the spatial orientation factor between the emission
dipole of the donor and the absorption dipole of the acceptor. The
dipole orientation factor, k2, is the least certain parameter in
calculation of the critical transfer distance, R0. Although theore-
tically k2 can range from 0 to 4, the extreme values require very
rigid orientations. If both the donor and acceptor are tumbling
rapidly and free to assume any orientation, then k2 equals 2/3 [33].
If only the donor is free to rotate, then k2 can vary from 1/3 to 4/3
[34,35], n is the refractive index of the medium, Φ is the
ﬂuorescence quantum yield of the donor and J is the overlap
integral of the ﬂuorescence emission spectrum of the donor and the
absorption spectrum of the acceptor, given by
J ¼
P
FðλÞεðλÞλ4ΔλP
FðλÞΔλ ð8Þ
where F(λ) is the ﬂuorescence intensity of the ﬂuorescent donor in
wavelength λ, and is dimensionless, ε(λ) is the molar absorption
coefﬁcient of the acceptor in wavelength λ and its unit is
L/cmmol. J can be evaluated by integrating the spectra in
Fig. 7. It has been reported for BSA and HSA that k2¼2/3,
Φ¼0.15 and n¼1.36 [29]. From Eqs. (8)–(10), we could calculate
that J¼0.17 1015 cm3 L/mol, E¼0.1211, R0¼2.79 nm, and
r¼3.885 nm. The average distance of 2–8 nm between a donor
and acceptor indicated that the energy transfer from HSA to SMZ
occurred with high probability [36]. The larger value of r
compared to that of R0 in the present study also revealed the
presence of static type quenching mechanism [16]. These values
are rather approximate. However, the distances obtained this way
agree well with literature values of substrate binding to HSA at site
IIA [37,38].
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Cyclic voltammograms of SMZ in the presence of HSA showed that
SMZ had an oxidation peak at 908 mV when HSA was added to the
SMZ solution, the oxidation peak shifted towards high potential and
decrease of the oxidation current was observed. Cyclic voltammo-
grams of SMZ in the presence of HSA showed irreversible process
(Fig. 8). At the HSA concentration of 1.25 mM, the oxidation peak
shifted to 920 mV. Furthermore, the concentration of free SMZ at
the electrode surface decreased during the experiment and the peak
current was also reduced consequently, the observed potential can
be attributed to the changes of the molecular environment of SMZ
as a result of its interaction with HSA. Assuming that the interaction
of SMZ and HSA produces only a single HSA/mSMZ molecular
complex, the binding constant β can be determined as follows [39]:
Given that
HSAþ mSMZ¼HSASMZ
HSAþ mSMZ⇌β ½HSASMZ
β¼ ½HSASMZ½SMZm½HSA ð9Þ
by using the relationships (10)–(13), Eq. (14) can be derived.
These relate the changes in the measured current, ΔI, to the
[SMZ]. From these equations, m and β may be extracted.
CHSA ¼ ½HSA þ ½HSASMZ ð10Þ
ΔI ¼ k½HSASMZ ð11Þ
ΔImax ¼ k CHSA ð12Þ
ΔImaxΔI ¼ k½HSA ð13Þ
And the ﬁnal equation is
log
ΔI
ΔImaxΔI
 
¼ log β þ m log SMZ½  ð14Þ
where ΔI is the peak current change of the responses measured at
the same concentration of SMZ in the absence or presence of
HSA, ΔImax is the maximum peak current change. TheFig. 8 Cyclic voltammograms of SMZ mixed with different con-
centrations of HSA. CSMZ¼1 104 mol/L (a), CHSA¼1.25 106
(b), 5 106 (c), 7.5 106 (d), 10 106 mol/L (e) and
12.5 106 mol/L (f).concentration of HSA was kept constant at 1.0 mM and the
concentration of added SMZ was in the range of 100–200 mM.
Thus, the resulting linear plot (Fig. 9) gave an m value of
0.96770.04 and β of (0.8870.2) 104 L/mol.
3.8. HSA unfolding pathways
The acid- and urea-induced unfolding pathways were employed to
locate the binding site for SMZ on HSA. HSA undergoes N-F and
N-I transitions induced by the acidic pH between 7.0 and 3.5 and
the urea concentration in the range of 4.8–5.2 M [40]. The F
isomer which predominates at pH 3.5, is characterized by
unfolding and separation of domain III and the I isomer is
characterized by unfolding of domain III and partial but signiﬁcant
loss of native conformation of domain I. Domain II is known to
persist in both N-F or N-I transitions. Fig. 10 shows
conformation-dependent binding of SMZ to HSA. Hence, a small
decrease in the number of binding sites of these conformational
states compared to native (Table 2) is suggestive of the location of
the binding sites for SMZ on domain II. The small decrease in the
n and K values (Table 2) may be due to a loss of inter-domain
interactions which stabilizes the protein domain structure. This is
justiﬁed to predict that a domain in the presence of its other
supportive unfolded domains cannot fully reﬂect its functional and
its structural properties.
3.9. Molecular modeling of SMZ binding to HSA
To further obtain the information of the right site and interaction
forces of SMZ binding to HSA, Autodock 3.05 was applied to
deduce the binding mode of SMZ in HSA. Crystal structure of
HSA shows that HSA is a heart-shaped helical monomer of 66 kD
composed of three similar homologous domains named I (residues
1–195), II (196–383) and III (384–585) and each domain includes
two subdomains called A and B to form a cylinder and each
subdomain involves 6 and 4 α-helixes, respectively, the only Trp
residue (Trp214) is located in subdomain IIA [41]. Almost all
hydrophobic amide acids are embedded in the cylinders and form
hydrophobic cavities, which play an important role on absorption,
metabolism, and transportation of biomolecules. The three
domains have similar 3D structures, and their assembly is highly
asymmetric. Domains I and II are perpendicular to each other,
forming a T-shaped assembly in which the tail of subdomain IIA is
attached to the interface region between subdomain IA and IB byFig. 9 The plot of log ΔI/(ΔImaxΔI) vs. log[SMZ] of HSA–SMZ
system at 288 K.
P.N. Naik et al.150hydrophobic and hydrogen bonds [42]. Despite the internal
structural symmetry of the three domains, they have different
capacities for binding drugs. In the structure of HSA, there are two
primary sites called site I (classical example is warfarin) and site II
(classical example is diazepam) for binding a wide variety of
drugs. The inside wall of the pocket of subdomain IIA correspond-
ing to the so-called site I is formed by hydrophobic side chains,
whereas the entrance of the pocket is surrounded by positively
charged residues such as Arg257, Arg222, Lys199, His242,
Arg218, and Lys195. Site II corresponds to the pocket with
hydrophobic side chains in subdomain IIIA, which is almost the
same size as site I. The third site in D-shaped cavity of subdomain
IB named site III is typical for binding hemin [43]. Unlike
subdomain IIA and IIIA, subdomain IA has no pocket near its
hydrophobic core. In the subdomain IA, the fourth helix is ﬂabby,
so it is cannot keep parallel to the third helix and bury the putative
pocket, but thanks to the interaction of subdomain IIIA with them,
the region is sealed to form site III. Although examples of drugs
binding elsewhere on the protein have been reported, most
investigations have focused on the three primary binding sites.
HSA is a ﬂexible protein that easily changes its molecular shape
due to the relative motions of domain structures.
Through molecular modeling by Autodock 3.05, the optimum
binding mode and site are displayed in Fig. 11. It can be seen that
the entrance of site I, a small cavity with positive charged residues
formed by interaction between subdomain IIA and IB, is the
possible binding site. But SMZ might be considered to be
unionized under the experimental conditions, as can be expected
from its structure. Thus, electrostatic interaction cannot play a
major role during the binding and SMZ bound to HSA is mainly
based on the hydrogen bonding and hydrophobic interaction. In
the region of SMZ (Fig. 11), there are 16 amino acids residues.Fig. 10 The plot of log(F0F)/F vs. log[Q] for N (a), I (b) and F (c)
conformation of HSA for binding constant and binding sites (λex¼280
nm, λem¼344 nm, CSMZ¼2.5–40 mM and CHSA¼5 mM).
Table 2 Comparative assessment of quenching constants and SMZ
HSA Binding constant (K) ( 104 L/mol)
Native (N) 1.73270.005
Fast moving (F) 0.54170.004
Urea indused (I) 0.33070.001Among them only two were hydrophobic residues (Pro147,
Phe149), ﬁve residues had positive charge (Lys106, Arg197,
Lys199, His242, Arg257) and the rest were polar residues
(Gln29, Tyr148, Tyr150, Gln196, Cys200, Cys245, Cys246,
Gly248, Cys253). On account of the unionized property of SMZ
under the physiological condition, it can be concluded that
hydrogen bonding is one of the major forces of interaction
between SMZ and HSA.
Furthermore, owing to the phenyl moiety of Phe149 exposed
close to the A ring in SMZ with additional aliphatic contact from
Arg197, His242 and Arg257, in addition, phenyl of Tyr148
approaches the ring B of SMZ at nearly vertical orientation and
Tyr150 is close tightly to the ring B of SMZ at an angle of about
601 from another side of SMZ, it is concluded that hydrophobic
force is another major force on the binding between SMZ and
HSA. Attributed to SMZ binding to nearby Tyr148 and Tyr150,
the phenyl of Trp214 faced slantingly to the hydrophobic part on
the side of A-ring in SMZ, which suggests that when SMZ moves
close enough to Trp214 during the dynamic equilibrium, the
ﬂuorescence energy of Trp can transfer to SMZ to bring the
quenching, so the ﬂuorescence quenching of HSA induced by
binding of SMZ resulted from not only Tyr148 and Tyr150 but
also Trp214, which agreed with the result of the synchronous
ﬂuorescence. According to references a wide range of biomole-
cules can be accommodated in site I, and the interaction between
biomolecules and HSA appears to be dominated by hydrophobic
contacts, but there are a number of speciﬁc electrostatic interac-binding parameters to HSA conformers.
Number of binding sites (n) ΔG0 (kJ/mol)
1.06 24.275.0
0.88 21.373.0
0.86 20.171.0
Fig. 11 Modeling of X-ray crystallographic structure of HSA
complexed with SMZ. The SMZ was shown in the entrance of site
I. The domains and subdomains were displayed with different colors,
the every subdomain and classical binding site were marked in the
corresponding location.
Table 3 Effect of anions and cations on binding constant of HSA–SMZ system.
Systems Binding constant (L/mol)
HSAþSMZ (1.56070.003) 104
HSAþSMZþMg2þ (2.23070.008) 103
HSAþSMZþCo2þ (8.37170.006) 102
HSAþSMZþNi2þ (1.89070.003) 103
HSAþSMZþV5þ (7.69170.003) 102
HSAþSMZþKþ (1.07170.004) 103
HSAþSMZþNO3 (1.03070.001) 102
HSAþSMZþSO42 (1.11270.006) 102
HSAþSMZþCH3COO (3.46370.005) 103
Binding study of human serum albumin by sulfamethoxazole 151tions [44]. The results suggested unanimously that hydrophobic
and hydrogen bonding plays an important role in the interaction
between SMZ and HSA.
3.10. Effects of other ions on the interactions of SMZ with HSA
In plasma, there are some metal ions which can affect the reactions
of the drugs and serum albumins. Trace metal ions, especially the
bivalent type, are essential in the human body and play an
important structural role in many proteins. It was reported [45]
that Mg2þ, Ni2þ, Co2þ and V5þ and other metal ions could form
complexes with serum albumins. Hence, the effects of some metal
ions: Mg2þ, Ni2þ, Co2þ, V5þ, NO3
 , SO4
2 and CH3COO
 on the
binding of SMZ to HSA were investigated in the present study.
The binding constants of SMZ–HSA in the presence of above ions
were evaluated and these results are shown in Table 3. The binding
constants of SMZ–HSA systems decreased in various degrees in
the presence of Mg2þ, Ni2þ, Co2þ, V5þ, NO3
 , SO4
2 and
CH3COO
 . This was likely to be caused by a conformational
change in the vicinity of the binding site. The decrease in the
binding constant in the presence of the above metal ions would
shorten the storage time of the drug in blood plasma and hence
more amount of free drug would be available in plasma [20]. This
led to the need for more doses of SMZ to achieve the desired
therapeutic effect in the presence of the above ions.4. Conclusions
In the present work, the binding of SMZ to HSA was carried out
employing spectroscopic techniques under physiological condi-
tions. Various binding parameters have been evaluated. The
decreasing values of K with an increase in temperature indicated
the presence of static quenching mechanism. The values of n
revealed the presence of a single class of binding site on HSA for
SMZ. Thermodynamic parameters indicated that the hydrogen
bonding and weak van der Waals interaction were the predominant
intermolecular force stabilizing the complex. The distance r
between the donor and the acceptor was obtained based on
ﬂuorescence resonance energy transfer. The spectroscopic results
revealed the changes in the secondary structure of HSA in the
presence of SMZ. The decreasing K values of SMZ–HSA
complexes in the presence of common ions indicated the avail-
ability of higher concentrations of free drug. Since pharmaceutical
ﬁrms need standardized screens for HSA binding in the ﬁrst step of
new drug design, this kind of study on interaction between HSA
and SMZ would be useful in pharmaceutical industry, chemistry,
life sciences and clinical medicine.Acknowledgments
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